ロード中...
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
BACKGROUND: The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external validation of the potential biomarkers CLU, ITGB3...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2754489/ https://ncbi.nlm.nih.gov/pubmed/19775429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-336 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|